Eton Pharmaceuticals, Inc. ETON

What this company does

Eton currently has eight commercial rare disease products: INCRELEX, ALKINDI SPRINKLE, KHINDIVI, GALZIN, PKU GOLIKE, Carglumic Acid, Betaine Anhydrous, and Nitisinone. Eton has five additional product candidates in late-stage development: ET-600, Amglidia, ET-700, ET-800 and ZENEO hydrocortisone autoinjector. INCRELEX is a biologic product that was approved by the FDA in August 2005 as a treatment for children who suffer from severe primary insulin-like growth factor 1 deficiency (SPIGFD). GALZIN is FDA-approved as a maintenance treatment for patients with Wilson disease who have been initially treated with a chelating agent. At December 31, 2025, Eton had 44 full-time employees, twelve of whom are engaged in research and development activities, twenty-four are engaged in sales and marketing operations and eight of whom are engaged in general corporate and strategy roles. Eton was incorporated under the laws of the state of Delaware in April 2017.

Written from the business description in Eton Pharmaceuticals, Inc.'s annual report to the U.S. Securities and Exchange Commission, filed 19 March 2026. Every sentence was checked against that document before publication.